167 related articles for article (PubMed ID: 30786705)
1. Active and Passive Smoking, BRAFV600E Mutation Status, and the Risk of Papillary Thyroid Cancer: A Large-Scale Case-Control and Case-Only Study.
Kim KN; Hwang Y; Kim K; Lee KE; Park YJ; Choi JY; Park DJ; Cho B; Kang D; Park SK
Cancer Res Treat; 2019 Oct; 51(4):1392-1399. PubMed ID: 30786705
[TBL] [Abstract][Full Text] [Related]
2. Association Between Obesity and BRAFV600E Mutation Status in Patients with Papillary Thyroid Cancer.
Lee J; Lee CR; Ku CR; Kang SW; Jeong JJ; Shin DY; Nam KH; Jung SG; Lee EJ; Chung WY; Jo YS
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S683-90. PubMed ID: 26215201
[TBL] [Abstract][Full Text] [Related]
3. The Clinicopathological Results of Thyroid Cancer With BRAFV600E Mutation in the Young Population of Fukushima.
Iwadate M; Mitsutake N; Matsuse M; Fukushima T; Suzuki S; Matsumoto Y; Ookouchi C; Mizunuma H; Nakamura I; Nakano K; Sakamoto A; Hirokawa M; Ito M; Naganuma H; Hashimoto Y; Shimura H; Yamashita S; Suzuki S
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32827026
[TBL] [Abstract][Full Text] [Related]
4. Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma.
Yoon JH; Han K; Lee E; Lee J; Kim EK; Moon HJ; Park VY; Nam KH; Kwak JY
PLoS One; 2020; 15(2):e0228968. PubMed ID: 32053670
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.
Chen B; Shi Y; Xu Y; Zhang J
Clin Endocrinol (Oxf); 2021 May; 94(5):731-742. PubMed ID: 32816325
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050
[TBL] [Abstract][Full Text] [Related]
7. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
[TBL] [Abstract][Full Text] [Related]
8. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
[TBL] [Abstract][Full Text] [Related]
9. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience.
Pelizzo MR; Boschin IM; Barollo S; Pennelli G; Toniato A; Zambonin L; Vianello F; Piotto A; Ide EC; Pagetta C; Sorgato N; Torresan F; Girelli ME; Nacamulli D; Mantero F; Mian C
Clin Chem Lab Med; 2011 Feb; 49(2):325-9. PubMed ID: 21175381
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
[TBL] [Abstract][Full Text] [Related]
11. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
12. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Nozhat Z; Fanaei SA; Hedayati M; Azizi F
Life Sci; 2019 Apr; 223():166-173. PubMed ID: 30890403
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the association of BRAFV600E mutation and Ki-67 overexpression with clinical and pathological characteristics in papillary thyroid cancer.
Espenbetova M; Krykpayeva A; Zamanbekova Z; Zhumanbaeva Z; Azizov B; Mukanova A; Glushkova N
Radiat Environ Biophys; 2021 May; 60(2):233-241. PubMed ID: 33774706
[TBL] [Abstract][Full Text] [Related]
15. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
16. Targeting of the BRAF gene in papillary thyroid carcinoma (review).
Li Y; Nakamura M; Kakudo K
Oncol Rep; 2009 Oct; 22(4):671-81. PubMed ID: 19724843
[TBL] [Abstract][Full Text] [Related]
17. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
Czarniecka A; Kowal M; Rusinek D; Krajewska J; Jarzab M; Stobiecka E; Chmielik E; Zembala-Nozynska E; Poltorak S; Sacher A; Maciejewski A; Zebracka-Gala J; Lange D; Oczko-Wojciechowska M; Handkiewicz-Junak D; Jarzab B
PLoS One; 2015; 10(7):e0132821. PubMed ID: 26177218
[TBL] [Abstract][Full Text] [Related]
18. A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer.
Takacsova E; Kralik R; Waczulikova I; Zavodna K; Kausitz J
Neoplasma; 2017; 64(1):156-164. PubMed ID: 27881018
[TBL] [Abstract][Full Text] [Related]
19. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract][Full Text] [Related]
20. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]